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Abstract
Dietary flavanols and flavonols, flavonoid subclasses, have been recently associated with a lower risk of type 2 diabetes
(T2D) in Europe. Even within the same subclass, flavonoids may differ considerably in bioavailability and bioactivity. We
aimed to examine the association between individual flavanol and flavonol intakes and risk of developing T2D across
European countries. The European Prospective Investigation into Cancer and Nutrition (EPIC)–InterAct case-cohort study
was conducted in 8 European countries across 26 study centers with 340,234 participants contributing 3.99 million
person-years of follow-up, among whom 12,403 incident T2D cases were ascertained and a center-stratified subcohort of
16,154 individuals was defined. We estimated flavonoid intake at baseline from validated dietary questionnaires using a
database developed from Phenol-Explorer and USDA databases. We used country-specific Prentice-weighted Cox
regression models and random-effects meta-analysis methods to estimate HRs. Among the flavanol subclass, we
observed significant inverse trends between intakes of all individual flavan-3-ol monomers and risk of T2D in multivariable
models (all P-trend < 0.05). We also observed significant trends for the intakes of proanthocyanidin dimers (HR for the
highest vs. the lowest quintile: 0.81; 95% CI: 0.71, 0.92; P-trend = 0.003) and trimers (HR: 0.91; 95% CI: 0.80, 1.04;
P-trend = 0.07) but not for proanthocyanidins with a greater polymerization degree. Among the flavonol subclass, myricetin
(HR: 0.77; 95% CI: 0.64, 0.93; P-trend = 0.001) was associated with a lower incidence of T2D. This large and heterogeneous
European study showed inverse associations between all individual flavan-3-ol monomers, proanthocyanidins with a low
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polymerization degree, and the flavonol myricetin and incident T2D. These results suggest that individual flavonoids have
different roles in the etiology of T2D. J. Nutr. 144: 335–343, 2014.
Introduction
Prospective studies have shown that the consumption of plant-
based foods, such as fruit and vegetables (1), tea (2), andwine (3,4),
is related to a lower risk of type 2 diabetes (T2D)37. Flavonoids and
other polyphenolic compounds may play a relevant role in the
health effects of plant-based diets, but the evidence is limited.
Flavonoids are a large group of secondary metabolites in plants
that comprise 6 subclasses: flavanols or flavan-3-ols (flavan-3-ol
monomers, proanthocyanidins, and theaflavins), anthocyanidins,
flavonols, flavanones, flavones, and isoflavones.
We recently reported that diets rich in flavonoids are
associated with a lower incidence of T2D in the European
Prospective Investigation into Cancer and Nutrition (EPIC)–
InterAct study (5). In particular, flavanols (including flavan-3-ol
monomers and theaflavins, but not proanthocyanidins) and
flavonols were the flavonoid subclasses that were significantly
inversely associated with T2D (5). Similar results for flavonol
intake were reported in a Finnish study (6), whereas no
association for these flavonoids was observed in studies
conducted in the United States (3,7,8). As a result of consider-
able differences in their chemical structure, there are large
differences in bioavailability (from 0.1% of some anthocyani-
dins to 50% of some isoflavones) and bioactivity between
different types of flavonoids (9,10). To our knowledge, only the
Finnish (6) and 1 of the U.S. studies (8) have assessed the effect
of the intake of some individual flavonoids (flavonols and
flavanones, and flavonols and flavones, respectively) on the risk
of T2D. An inverse trend between quercetin and myricetin
intake and T2D incidence was observed only in the Finnish study
(6). Therefore, distinction within different subclasses (individual
flavonoids) is recommended in studies assessing their health
effects.
The aim of the present study was to investigate the associ-
ation between dietary individual flavanol and flavonol intakes,
which are the 2 flavonoid subclasses previously related to T2D in
the EPIC-InterAct study (5), and the risk of developing T2D in a
Europe-wide population with a large heterogeneity in the intake
of these compounds (11,12).
Participants and Methods
Study design, population, and case ascertainment. The rationale
and design of the EPIC-InterAct study have been previously published
(13). In short, EPIC-InterAct is a case-cohort study nested within the
EPIC study (14), comprising cohorts recruited in the 1990s from 8
European countries (Denmark, France, Germany, Italy, The Nether-
lands, Spain, Sweden, and the United Kingdom) across 26 participating
study centers (13). Detailed information on numbers by country and
center was provided previously (13), but, in summary, of the 455,680
participants across the 8 countries of EPIC, after the exclusion of
individuals without stored blood (n = 109,625) or without information
on reported diabetes status (n = 5821), 340,234 participants with 3.99
million person-years of follow-up were eligible for this study. Ethical
review boards of the International Agency for Research on Cancer and
local participating centers approved the project.
We identified and verified cases of incident T2D by using multiple
data sources of evidence, including self-report, linkage to primary care
registers, secondary care registers, medication registers, hospital admis-
sions, and mortality data (13). Follow-up was censored on 31 December
2007 or the date of death or T2D diagnosis, whichever occurred first. In
total, we identified 12,403 verified incident cases of T2D.
We randomly selected a center-stratified subcohort of 16,835
individuals from the 340,234 eligible participants. After exclusion of
participants with prevalent diabetes or unknown diabetes status (n =
681), 16,154 individuals were included in the subcohort. Because of
random selection, this subcohort also included a random set of 778
individuals who developed incident T2D during follow-up. The case-
cohort design allows for the random occurrence of incident cases in the
subcohort and accounts for this in the statistical analysis.
Of the 27,779 participants, we excluded 619 participants with a ratio
of energy intake to energy expenditure in the top and bottom 1% of the
distribution and 1072 participants with missing information on dietary
intake or other covariates used in the statistical analysis. The final
analysis sample included 26,088 participants (11,559 cases and a
subcohort of 15,258 participants, including 729 cases in the subcohort).
Data collection. At baseline, usual dietary intake during the year before
recruitment was measured by country-specific validated dietary ques-
tionnaires designed to reflect local dietary patterns (14,15).We estimated
total energy and nutrient intakes by using the standardized EPIC
Nutrient Database (16).
We obtained baseline information on other lifestyle variables from
face-to-face or self-administered and standardized questionnaires including
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questions on education, medical history, physical activity, and smoking
(14,17). We measured anthropometric data by using standardized
protocols, except in Oxford (UK) and France, where we collected self-
reported measurements (14).
Flavanol and flavonol intake. Estimated flavanol and flavonol intakes
were derived from foods included in the dietary questionnaires through a
comprehensive food composition database on flavonoids as previously
described (11,12,18). Our database on flavanols (flavan-3-ol monomers,
proanthocyanidins, and theaflavins) and flavonols was based on USDA
databases (19,20) and Phenol-Explorer (21). This online database
compiles composition data on individual flavan-3-ol monomers (cate-
chin, epigallocatechin, epicatechin, epicatechin 3-gallate, epigallocate-
chin 3-gallate, gallocatechin, catechin 3-gallate), proanthocyanidin
groups (dimers, trimers, 4–6 monomers, 7–10 monomers, polymers),
and the individual flavonols (isorhamnetin, kaempferol, myricetin,
quercetin). Data on flavonoids were expressed as aglycone equivalents,
after conversion of the flavonoid glycosides into aglycone contents using
their respective molecular weights. The final database contains 1877
food items, including raw foods, cooked foods, and recipes, and 10% of
values for these food items are missing.
Statistical analysis. We assessed the distributions of intakes of total
and individual flavan-3-ol monomers, proanthocyanidins, theaflavins,
and flavonols by using means, SDs, medians, and 5th and 95th
percentiles because the data were skewed to the right. We used Spearman
correlations to assess whether individual flavonoid intakes were corre-
lated to each other within the same flavonoid subclass. The contribution
of each food group to individual flavonoid intake was also computed as a
percentage. We examined baseline characteristics and dietary intakes in
the subcohort by quintiles of the sum of flavanol and flavonol intake.
Prentice-weighted Cox regression models (22), which account for the
case-cohort design, were used to estimate the associations between
intakes of individual flavan-3-ol monomers, proanthocyanidins, and
flavonols and risk of T2D. We categorized individual flavonoids by using
subcohort-wide quintiles. Tests for linear trend were performed by
assigning the medians of each quintile as scores. Intakes were also
analyzed continuously after a log2 transformation so that a 1-unit
increase represents a doubling of flavonoid intake. We estimated HRs
and their 95% CIs by using the following modeling strategy based on
already known confounding variables. Age was used as the underlying
time scale, with entry time defined as the participants age at baseline and
exit time as age at diagnosis of diabetes, censoring, or death (whichever
came first). All models were stratified by center to control for center
effects such as follow-up procedures and questionnaire design. Model
1 was adjusted for sex and total energy intake (kcal/d). Model 2 was
additionally adjusted for educational level (none, primary school,
technical/professional, secondary school, longer education), physical
activity index (inactive, moderately inactive, moderately active, and
active) (17), smoking status (never, former, and current), BMI (kg/m2),
and alcohol intake (g/d). Model 3 was additionally adjusted for intakes
of red meat, processed meat, sugar-sweetened soft drinks, and coffee (g/d).
Model 4 was additionally adjusted for intakes of fiber (g/d), vitamin C
(mg/d), and magnesium (mg/d). Models were not mutually adjusted for
the rest of flavonoids within the subclass because of the high correlations
between them (Supplemental Tables 1–3). We estimated HRs and their
95%CIs within each country and then combined them by using random-
effects meta-analysis. Between-country heterogeneity was assessed by using
the I2 statistic (23). Effect modification by sex, baseline BMI category (BMI
<25, 25 to < 30, and $30 kg/m2), and smoking status (never, former,
current smokers) were assessed by modeling interaction terms between these
variables and total intakes of flavan-3-ol monomers, proanthocyanidins,
and flavonols.
We conducted sensitivity analyses excluding incident T2D cases
diagnosed within the first 2 y of recruitment (n = 975). In a second
sensitivity analysis, model 4 was additionally adjusted for self-reported
hypertension and hyperlipidemia, after exclusion of 1971 participants
with cancer and/or cardiovascular diseases at recruitment, because these
subgroups may have modified their diet. In a third sensitivity analysis,
model 4 was additionally adjusted for history of diabetes in a first-degree
relative (after exclusion of 12,977 participants without these data), an
important risk factor for T2D (24); and finally, model 4 was additionally
adjusted for waist circumference (after exclusion of 1824 participants
without these data), another independent risk factor strongly associated
with T2D (25). All statistical analyses were performed by using Stata/SE
12.0 (StataCorp). All P values were based on 2-sided tests, and
significance was set at P < 0.05.
Results
Table 1 shows the mean (SD), median, and percentile (5th and
95th) of individual flavan-3-ol monomer, proanthocyanidin,
theaflavin, and flavonol intakes in the EPIC-InterAct subcohort.
As indicated by the large differences between means and medians,
particularly for flavan-3-ol monomers, the distributions were
skewed to higher values. Epigallocatechin 3-gallate was the
highest contributor (45.6%) to total flavan-3-ol monomer intake,
followed by epicatechin 3-gallate (14.2%), epigallocatechin (13.8%),
epicatechin (13.2%), catechin (9.2%), catechin 3-gallate (2.5%), and
gallocatechin (1.5%). Polymers represented the subclass of
proanthocyanidins that were most abundant (34.5%), followed
by 4–6 monomers (22.2%), dimers (18.9%), 7–10 monomers
(16.3%), and trimers (8.1%). Quercetin was the highest contributor
to flavonols (70.2%), followed by kaempferol (18.5%), myricetin
(9.3%), and isorhamnetin (2.0%). The main food sources of
flavan-3-ol monomers, proanthocyanidins, and flavonols are
shown in Table 1. Theaflavins were exclusively found in tea;
therefore, the association with T2D was not considered.
All flavan-3-ol monomer intakes were highly correlated with
each other (Supplemental Table 1), as were proanthocyanidins
(Supplemental Table 2) and flavonols, except for isorhamnetin
(Supplemental Table 3).
Participants in the highest quintile of total flavanol and
flavonol intakes were likely to be older with a greater educational
level and with a more health-conscious lifestyle pattern (more
physically active with lower BMI and tobacco consumption,
higher intakes of fiber, vitamin C, magnesium, fruit, and vegeta-
bles; and a lower consumption of processed meat compared with
those in the lowest quintile); however, participants in the top
quintile reported greater alcohol and red meat intake, and a lower
intake of coffee (Table 2). Participants across quintiles had similar
frequencies of prevalent diseases.
The pooled HRs (95% CIs) for T2D comparing quintiles of
individual flavan-3-ol monomer, proanthocyanidin, and flavo-
nol intakes are shown in Tables 3–5, respectively. We observed
statistically significant inverse associations in model 1 [stratified
by center and adjusted for age (as underlying time scale), sex,
and total energy] for all individual compounds, except for the
flavonol isorhamnetin. After further adjustment for potential
confounders (models 2 and 3), all associations were attenuated.
When we additionally included fiber, vitamin C, and magnesium
in the multivariable models (model 4), we observed significant
inverse trends between incidence of T2D and all individual
flavan-3-ol monomers, although the HR for the highest versus
the lowest quintile was only significant for epigallocatechin
3-gallate (HR: 0.64; 95% CI: 0.44, 0.92), catechin (HR: 0.86;
95% CI: 0.75, 0.99), catechin 3-gallate (HR comparing extreme
quantiles: 0.80; 95% CI: 0.69, 0.93), and gallocatechin (HR:
0.71; 95% CI: 0.59, 0.85). For proanthocyanidins, we found a
significant inverse association with dimers (HR: 0.81; 95% CI:
0.71, 0.92; P-trend = 0.003) and a borderline inverse trend
with trimers (HR: 0.91; 95% CI: 0.80, 1.04; P-trend = 0.07).
For flavonols, we found a significant inverse association with
myricetin (HR: 0.77; 95%CI: 0.64, 0.93; P-trend = 0.001) and a
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significant trend with kaempferol (HR: 0.91; 95% CI: 0.78,
1.05; P-trend = 0.013).
In multivariable analyses (model 4), we observed similar
associations of T2D when dietary flavan-3-ol monomer,
proanthocyanidin, and flavonol exposures were assessed as a
continuous variable after log2 transformation (Tables 3–5). We
detected no significant heterogeneity between countries for the
associations of flavan-3-ol monomers (I2 = 19.4%, P = 0.28),
proanthocyanidins (I2 = 0.0%, P = 0.77), and flavonols (I2 =
26.8%, P = 0.21) with T2D. For intakes of flavan-3-ol
monomers, proanthocyanidins, and flavonols, we found no
interactions with sex (P-interaction = 0.44, 0.45, and 0.12,
respectively), BMI (P-interaction = 0.75, 0.73, and 0.83,
respectively), or smoking status (P-interaction = 0.18, 0.79,
and 0.23, respectively).
In sensitivity analyses, we observed similar results after the
exclusion of T2D cases diagnosed within the first 2 y of follow-up
or participants with prevalent cardiovascular diseases. When
family history of diabetes was added in model 4, associations
were strengthened. After further adjustment for waist circumfer-
ence (model 4), the findings were almost identical (data not shown).
Discussion
In this large prospective study across 8 European countries, all
flavan-3-ol monomers, proanthocyanidins with lower degree of
polymerization, and the flavonol myricetin were inversely
related to a lower risk of T2D. We found inverse trends between
all individual flavan-3-ol monomer intakes and risk of T2D.
Furthermore, among them, intakes of catechin, epigallocatechin
3-gallate, gallocatechin, and catechin 3-gallate were significantly
inversely associated with incident T2D comparing extreme
quantiles. Indeed, the main food sources of flavan-3-ol mono-
mers (tea and some fruit, particularly apples and pears) in the
EPIC study (11) were also inversely associated with incidence of
T2D in several prospective studies (1,2,7,26). In contrast to our
findings, no associations between flavanols and T2D were
reported in any of the previous cohorts conducted in the United
States (3,7). Differences in the range of intakes between
countries could partially explain these inconsistencies. In the
present European study, the median of flavan-3-ol monomer
intake was 41.4 mg/d (10th–90th percentiles: 12.9–428.9 mg/d),
whereas in 1 of the U.S. studies the median was 27.0 mg/d (10th–
90th percentiles: 8.4–135.1 mg/d) (7). Several in vitro and in
vivo studies have evaluated the antidiabetic effects of individual
flavan-3-ol monomers and flavan-3-ol–rich foods (e.g., cocoa
and tea), showing a high range of activities related to improving
glucose homeostasis, such as inhibition of glucosidase activity
and glucose absorption from the intestine, protection of pancreatic
b cells, increased insulin secretion, activation of insulin receptors
and glucose uptake in the insulin-sensitive tissues, and modulation
of intracellular signaling pathways and genes involved in gluco-
neogenesis and glycogenesis (27–29).
As reported earlier, in the EPIC-InterAct study (5) and in a
U.S.-based study (3), total proanthocyanidin subclass intake was
not significantly related to T2D. However, examining the
relations of dietary proanthocyanidins according to polymeri-
zation degree in the current study, a significant inverse associ-
ation was observed between proanthocyanidin dimer intakes
and risk of T2D. Moreover, a potential trend with proantho-
cyanidin trimer intake was found, but not with PAs with higher
polymerization degrees. These results might be interpreted in 3
different ways. First, proanthocyanidin dimers are more bioac-
tive than proanthocyanidin polymers. In the gut, proanthocya-
nidins inhibit the glucosidase activity and the formation of
advanced glycation endproducts in an inverse polymerization
degree manner; however, proanthocyanidin polymers showed a
stronger inhibitory activity against a-amylase than did proan-
thocyanidin oligomers (30). Second, proanthocyanidin dimers
and trimers are more bioavailable than polymers, and, as such,
they can be better absorbed in the gut than proanthocyanidin
polymers (9). Several pharmacokinetic studies have shown that
proanthocyanidin polymers may not be degraded to monomers in
the stomach (31) and polymerization greatly impairs intestinal
TABLE 1 Dietary intake of flavanols and flavonols in the EPIC-InterAct subcohort1
Flavonoid Mean 6 SD Median (5th, 95th percentile) Main food sources
Flavanols, mg/d 334 6 286 246 (60.9, 938) Tea (39.1%), fruit (34.2%), wine (7.9%), chocolate (5.0%)
Flavan-3-ol monomers 146.2 6 228.7 41.4 (9.2, 711.2) Tea (81.0%), fruit (7.1%), wine (3.4%), chocolate (3.0%)
(2)-Epigallocatechin 3-gallate 66.7 6 124.8 4.9 (0.2, 375.8) Tea (97.0%), chocolate (1.6%), cakes (0.6%), fruit (0.5%)
(2)-Epicatechin 3-gallate 20.7 6 36.7 3.0 (0.0, 110.3) Tea (91.9%), herbal tea (5.5%), chocolate (1.2%), beer and cider (0.5%)
(2)-Epigallocatechin 20.2 6 35.3 3.0 (0.5, 107.1) Tea (91.3%), fruit (3.8%), beer and cider (2.5%), coffee (0.8%)
(2)-Epicatechin 19.3 6 18.0 13.6 (3.2, 57.0) Tea (40.4%), fruit (27.4%), chocolate (11.4%), wine (8.2%)
(+)-Catechin 13.5 6 10.7 10.6 (2.7, 34.1) Fruit (29.7%), wine (24.3%), tea (22.1%), beer and cider (9.8%)
(+)-Catechin 3-gallate 3.6 6 6.8 0.3 (0.0, 20.3) Tea (98.3%), herbal tea (1.7%)
(+)-Gallocatechin 2.2 6 3.9 0.3 (0.0, 11.7) Tea (93.8%), beer and cider (3.6%), fruit (0.4%), legumes (0.1%)
Proanthocyanidins 183 6 140 151 (41.7, 423) Fruit (56.8%), wine (11.7%), chocolate (6.8%), juices (4.5%)
Dimers 34.5 6 29.5 26.8 (6.3, 86.4) Fruit (38.0%), wine (25.7%), tea (17.8%), chocolate (5.6%)
Trimers 14.8 6 12.3 12.1 (3.1, 34.7) Fruit (52.2%), juices (11.4%), chocolate (8.8%), tea (7.4%)
4–6mers 40.6 6 32.4 32.9 (8.5, 96.1) Fruit (62.7%), chocolate (9.0%), wine (8.6%), juices (4.2%)
7–10mers 29.8 6 24.8 23.8 (5.4, 73.5) Fruit (64.9%), wine (8.7%), chocolate (6.1%), legumes (5.4%)
Polymers 63.0 6 50.2 51.3 (12.5, 147.9) Fruit (60.4%), wine (9.1%), legumes (7.8%), chocolate (5.9%)
Theaflavins 4.6 6 8.8 0.08 (0, 26.4) Tea (100%)
Flavonols, mg/d 24.8 6 16.0 20.4 (7.8, 57.4) Vegetables (27.2%), tea (26.4%), fruit (15.6%), wine (7.3%)
Quercetin 17.4 6 10.0 15.1 (5.7, 36.8) Vegetables (29.0%), fruit (21.1%), tea (20.3%), wine (6.6%)
Kaempferol 4.6 6 5.1 2.6 (0.4, 15.1) Tea (44.4%), vegetables (27.8%), beer and cider (17.4%), wine (2.8%)
Myricetin 2.3 6 2.4 1.3 (0.3, 7.7) Tea (51.8%), wine (22.1%), coffee (8.9%), vegetables (4.5%)
Isorhamnetin 0.5 6 0.6 0.4 (0.1, 1.6) Vegetables (58.8%), fruit (16.4%), wine (6.6%), herbal tea (4.2%)
1 n = 15,258. EPIC, European Prospective Investigation into Cancer and Nutrition; 4–6mers, 4–6 monomers; 7–10mers, 7–10 monomers.
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absorption (9). In experimental studies, proanthocyanidin dimers
improved insulin concentrations in the blood and pancreas (32). In
addition, proanthocyanidins were able to regulate microRNA
expression in human HepG2 cells, suggesting a new antidiabetic
mechanism of action of proanthocyanidins (33). Third, proantho-
cyanidins not absorbed in the gut are partially hydrolyzed in
the colon by the intestinal microbiota, taking into account that
their degradation into phenolic acids decreases as the degree
of polymerization increases (34). After proanthocyanidin hydro-
lyzation, phenolic acids can be absorbed in the colon, and then
those may exert their antidiabetic effects, such as increasing
insulin secretion, improving glucose uptake in muscle cells, and
inducing hepatic glucokinase activity (28). These findings
suggest a different effect of proanthocyanidins by polymeriza-
tion degree in T2D, highlighting that a role in the prevention of
T2D for proanthocyanidins may be confined to dimers and
probably trimers but not to proanthocyanidins with a greater
polymerization degree.
TABLE 2 Baseline characteristics and dietary intakes of the EPIC-InterAct subcohort according to
quintiles of sum of flavanol and flavonol intake1
Characteristic All (n = 15,258)
Quintile of sum of flavanols and flavonols
1 (n = 3052) 2 (n = 3052) 3 (n = 3051) 4 (n = 3052) 5 (n = 3051)
Cutoff, mg/d ,139.8 139.8–217.5 217.6–321.7 321.8–526.0 .526.0
Median intake, mg/d 97.6 176.6 265.2 397.1 713.6
Sociodemographic characteristics
Age, y 52.4 6 9.1 52.1 6 9.4 52.1 6 9.0 51.7 6 9.1 51.8 6 8.6 54.2 6 9.1
Men, % 37.8 40.3 35.8 34.6 38.7 39.8
Educational level, %
None 7.7 7.6 8.7 9.6 8.4 4.1
Primary school 33.3 40.3 33.9 33.4 31.7 27
Technical/professional 23.2 24.5 22.6 21.6 21.7 25.8
Secondary school 15.1 12.3 13.8 15.7 16.6 17.2
Longer education 20.7 15.3 21.1 19.6 21.7 25.9
Anthropometric characteristics
BMI, kg/m2 26.0 6 4.2 26.2 6 4.3 26.2 6 4.3 26.0 6 4.0 26.2 6 4.2 25.5 6 3.9
Waist circumference,2 cm 86.4 6 12.6 87.2 6 12.9 86.5 6 12.8 85.9 6 12.5 86.9 6 12.4 86.4 6 12.6
Lifestyle characteristics
Smoking status, %
Never 46.8 39.3 45.3 51.2 50.1 48.3
Former 27.2 23.4 26.0 25.0 28.9 32.5
Current 26.0 37.3 28.7 23.8 20.9 19.2
Physical activity, %
Inactive 23.6 27.5 26.3 24.0 21.4 18.9
Moderately inactive 33.7 33.9 34.0 33.5 35.3 31.5
Moderately active 22.7 21.5 20.5 23.8 22.4 25.1
Active 20.1 17.0 19.3 18.7 20.9 24.4
Prevalent diseases, yes, %
Cancer 3.2 3.6 3.7 2.8 3.1 3.1
Myocardial infarction2 1.4 1.8 1.8 0.9 1.0 1.5
Stroke2 0.9 1.3 1.0 0.6 0.6 0.8
Angina2 2.1 2.0 2.4 1.8 1.6 2.4
Hypertension2 18.6 18.3 20.0 19.4 18.0 17.2
Hyperlipidemia2 17.3 15.5 18.1 19.9 19.2 13.7
Family history of diabetes2 19.2 19.8 18.9 20.4 21.7 16.5
Dietary intake
Total energy, kcal/d 2140 6 635 1920 6 575 2080 6 594 2170 6 624 2260 6 650 2260 6 661
Alcohol, g/d 13.2 6 18.5 8.8 6 13.0 12.0 6 16.8 13.1 6 17.9 15.7 6 20.1 16.4 6 22.4
Fiber, g/d 22.8 6 7.8 18.1 6 5.9 21.3 6 6.4 23.0 6 6.8 25.3 6 7.5 26.3 6 8.9
Vitamin C, mg/d 124 6 68 88 6 52 116 6 58 128 6 61 145 6 68 142 6 79
Magnesium, mg/d 351 6 103 310 6 91 340 6 97 352 6 103 368 6 104 384 6 105
Red meat, g/d 46 6 36 45 6 36 45 6 35 44 6 35 46 6 34 50 6 40
Processed meat, g/d 37 6 32 38 6 31 40 6 34 38 6 33 36 6 33 32 6 31
Soft drinks, g/d 69 6 155 76 6 175 71 6 154 65 6 157 57 6 127 74 6 158
Coffee, g/d 384 6 385 496 6 436 433 6 405 350 6 365 303 6 327 337 6 349
Fruit, g/d 234 6 188 109 6 91 190 6 116 250 6 151 319 6 196 305 6 253
Vegetables, g/d 183 6 119 139 6 103 173 6 109 183 6 115 200 6 122 219 6 128
1 Values are means 6 SDs or percentages. EPIC, European Prospective Investigation into Cancer and Nutrition.
2 Missing data: waist circumference (n = 1013), myocardial infarction (n = 230), stroke (n = 1209), angina (n = 5139), hypertension (n = 45),
hyperlipidemia (n = 2944), family history of diabetes (n = 7643). Prevalent diseases were self-reported.
Flavanols and flavonols and type 2 diabetes 339
 at Cam
bridge University Library on July 10, 2014
jn.nutrition.org
D
ow
nloaded from
 
Among flavonols, myricetin was significantly inversely asso-
ciated with T2D, and kaempferol tended to be inversely related
to T2D risk. Similar results were reported for kaempferol and
quercetin in the Finnish study (6), but no significant associations
were observed for flavonol intakes in the U.S. studies (3,7,8).
Surprisingly, in our study, quercetin, which was the most
abundant contributor (70%) to flavonol intake, was not
associated with T2D, although we note that quercetin intake
was highly correlated with other flavonol intakes, except for
intakes of isorhamnetin. These nonsignificant results could be
explained by the wide CIs and the moderate heterogeneity
observed among countries in our pooled analysis (I2 = 44.5%,
P = 0.08). This heterogeneity may be related to the large
variability in quercetin intake among participating countries
(12). According to flavonol dietary sources (12), tea [a food
significantly associated with a lower incidence of T2D (2,26)]
was the main contributor to myricetin and kaempferol, whereas
vegetables and fruit were the main food sources of quercetin,
TABLE 3 Pooled HRs (95% CIs) for the association between flavan-3-ol monomer intakes and type 2 diabetes:
the EPIC-InterAct study1
Flavan-3-ol monomer Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P-trend2 Continuous (log2)
3
(2)-Epigallocatechin 3-gallate, mg/d ,0.87 0.87–2.40 2.41–11.64 11.65–108.77 .108.77
Median intake, mg/d 0.4 1.46 4.9 40.8 219.62
Model 1 1 (ref) 0.83 (0.73, 0.95) 0.78 (0.66, 0.94) 0.73 (0.59, 0.90) 0.57 (0.44, 0.73) ,0.001 0.96 (0.94, 0.98)
Model 2 1 (ref) 0.85 (0.74, 0.98) 0.89 (0.70, 1.13) 0.82 (0.63, 1.07) 0.69 (0.47, 1.01) 0.24 0.99 (0.97, 1.01)
Model 3 1 (ref) 0.86 (0.74, 1.00) 0.88 (0.69, 1.12) 0.80 (0.61, 1.04) 0.64 (0.45, 0.92) 0.008 0.98 (0.96, 1.00)
Model 4 1 (ref) 0.85 (0.74, 0.99) 0.87 (0.69, 1.11) 0.79 (0.60, 1.03) 0.64 (0.44, 0.92) 0.012 0.98 (0.96, 1.00)
(2)-Epicatechin 3-gallate, mg/d ,0.31 0.31–1.34 1.35–6.17 6.18–32.21 .32.21
Median intake, mg/d 0.11 0.6 2.98 15.08 64.48
Model 1 1 (ref) 0.88 (0.79, 0.98) 0.86 (0.73, 1.02) 0.77 (0.63, 0.94) 0.64 (0.51, 0.81) ,0.001 0.96 (0.95, 0.98)
Model 2 1 (ref) 1.00 (0.89, 1.11) 1.01 (0.81, 1.25) 0.96 (0.79, 1.17) 0.88 (0.66, 1.18) 0.54 1.00 (0.98, 1.01)
Model 3 1 (ref) 0.99 (0.88, 1.13) 0.99 (0.79, 1.23) 0.92 (0.74, 1.14) 0.80 (0.60, 1.06) 0.024 0.99 (0.97, 1.00)
Model 4 1 (ref) 1.00 (0.87, 1.15) 0.98 (0.77, 1.24) 0.90 (0.71, 1.15) 0.80 (0.59, 1.08) 0.031 0.98 (0.97, 1.00)
(2)-Epigallocatechin, mg/d ,1.09 1.09–2.05 2.06–5.33 5.34–31.36 .31.36
Median intake, mg/d 0.73 1.5 3.04 13.66 63.06
Model 1 1 (ref) 0.85 (0.78, 0.92) 0.87 (0.75, 1.01) 0.83 (0.69, 0.99) 0.64 (0.53, 0.79) ,0.001 0.95 (0.94, 0.97)
Model 2 1 (ref) 0.92 (0.81, 1.04) 0.98 (0.84, 1.14) 1.01 (0.85, 1.19) 0.81 (0.63, 1.05) 0.52 0.99 (0.97, 1.01)
Model 3 1 (ref) 0.95 (0.83, 1.08) 1.01 (0.86, 1.18) 1.02 (0.86, 1.21) 0.80 (0.63, 1.01) 0.020 0.98 (0.96, 1.00)
Model 4 1 (ref) 0.95 (0.85, 1.07) 1.00 (0.84, 1.19) 1.01 (0.83, 1.21) 0.79 (0.61, 1.03) 0.022 0.98 (0.96, 1.00)
(2)-Epicatechin, mg/d ,6.76 6.76–11.02 11.03–16.83 16.84–28.75 .28.75
Median intake, mg/d 4.56 8.81 13.62 21.02 41.35
Model 1 1 (ref) 0.90 (0.80, 1.01) 0.77 (0.68, 0.88) 0.73 (0.63, 0.85) 0.67 (0.53, 0.85) ,0.001 0.87 (0.82, 0.92)
Model 2 1 (ref) 0.98 (0.87, 1.10) 0.91 (0.82, 1.01) 0.89 (0.80, 1.00) 0.92 (0.77, 1.09) 0.24 0.95 (0.91, 0.99)
Model 3 1 (ref) 0.99 (0.88, 1.11) 0.92 (0.83, 1.02) 0.89 (0.77, 1.02) 0.87 (0.71, 1.06) 0.05 0.93 (0.89, 0.98)
Model 4 1 (ref) 0.99 (0.89, 1.11) 0.92 (0.82, 1.03) 0.87 (0.75, 1.01) 0.84 (0.69, 1.04) 0.040 0.93 (0.89, 0.98)
(+)-Catechin, mg/d ,5.50 5.50–8.79 8.80–12.78 12.79–20.08 .20.08
Median intake, mg/d 3.81 7.11 10.59 15.65 27.02
Model 1 1 (ref) 0.84 (0.73, 0.97) 0.75 (0.66, 0.86) 0.67 (0.57, 0.80) 0.64 (0.51, 0.80) ,0.001 0.84 (0.78, 0.91)
Model 2 1 (ref) 1.01 (0.87, 1.17) 0.92 (0.82, 1.03) 0.94 (0.84, 1.06) 0.98 (0.78, 1.02) 0.024 0.96 (0.93 0.99)
Model 3 1 (ref) 1.02 (0.88, 1.18) 0.93 (0.81, 1.06) 0.94 (0.84, 1.06) 0.87 (0.76, 1.00) 0.006 0.94 (0.90, 0.98)
Model 4 1 (ref) 1.01 (0.87, 1.18) 0.92 (0.79, 1.07) 0.93 (0.83, 1.05) 0.86 (0.75, 0.99) 0.005 0.94 (0.91, 0.98)
(+)-Catechin 3-gallate4, mg/d 0 0.01–0.50 0.51–5.65 .5.65 —
Median intake, mg/d 0 0.19 2.03 11.85 —
Model 1 1 (ref) 0.88 (0.77, 0.99) 0.84 (0.74, 0.95) 0.65 (0.57, 0.76) — ,0.001 0.99 (0.98, 0.99)
Model 2 1 (ref) 0.99 (0.85, 1.16) 0.96 (0.86, 1.07) 0.85 (0.72, 1.02) — 0.29 1.00 (0.99, 1.00)
Model 3 1 (ref) 0.99 (0.85, 1.15) 0.93 (0.83, 1.04) 0.78 (0.67, 0.91) — 0.006 1.00 (0.99, 1.00)
Model 4 1 (ref) 0.98 (0.84, 1.15) 0.93 (0.82, 1.05) 0.80 (0.69, 0.93) — 0.009 1.00 (0.99, 1.00)
(+)-Gallocatechin, mg/d ,0.04 0.04–0.18 0.19–0.59 0.60–3.45 .3.45
Median intake, mg/d 0.015 0.09 0.31 1.48 7.01
Model 1 1 (ref) 0.79 (0.69, 0.91) 0.78 (0.72, 0.86) 0.74 (0.62, 0.89) 0.58 (0.50, 0.68) ,0.001 0.96 (0.95, 0.97)
Model 2 1 (ref) 0.84 (0.65, 1.09) 0.88 (0.78, 0.99) 0.86 (0.70, 1.05) 0.75 (0.63, 0.89) 0.57 0.99 (0.97, 1.00)
Model 3 1 (ref) 0.87 (0.68, 1.12) 0.89 (0.80, 1.01) 0.85 (0.68, 1.06) 0.71 (0.59, 0.85) 0.022 0.98 (0.97, 0.99)
Model 4 1 (ref) 0.88 (0.68, 1.13) 0.89 (0.79, 1.00) 0.84 (0.68, 1.05) 0.71 (0.59, 0.85) 0.027 0.98 (0.97, 0.99)
1 For model 1, the pooled HRs were based on random-effects meta-analysis by using Prentice-weighted Cox regression analysis, stratified by center and adjusted for sex and total
energy intake. Model 2 was additionally adjusted for educational level, smoking status, physical activity levels, BMI, and alcohol intake. Model 3 was additionally adjusted for red
meat, processed meat, sugar-sweetened soft drinks, and coffee intakes. Model 4 was additionally adjusted for fiber, vitamin C, and magnesium intakes. EPIC, European
Prospective Investigation into Cancer and Nutrition; ref, reference.
2 Obtained by assigning the median of each quintile as scores.
3 A 1-unit increase represents a doubling of flavan-3-ol monomer intake.
4 Catechin 3-gallates were assessed in 4 groups because there was a large group of nonconsumers, which resulted in an unbalanced division of catechin 3-gallates in quintiles:
group 1, n = 9499 (36.4%); group 2, n = 5930 (22.7%); group 3, n = 5621 (21.6%); group 4, n = 5038 (19.3%).
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which are modestly associated with a lower incidence of T2D
(1). To our knowledge, all individual flavonols are able to inhibit the
activity of digestive enzymes for glucose production, particularly
a-amylase, as well as of the transporters responsible for glucose
absorption [sodium-glucose cotransporter 1 (SGLT1) and glucose
transporter 2 (GLUT2)] (28,35), although some differences in
dose-response effects between individual flavonols may occur.
Furthermore, enhanced pancreatic b-cell function and antioxidant,
anti-inflammatory, and antiangiogenic activities of flavonols, through
the regulation of signal transduction and different enzyme systems,
may also be involved in their potential role against T2D (36,37).
Limitations in our study included the use of a baseline
assessment of diet and other lifestyle variables. Therefore, changes
in lifestyle could not be taken into account in these analyses. In
addition, measurement error in collecting self-reported dietary
intake is inevitable. To minimize this, we used country-specific
validated questionnaires for main food groups and nutrients
(14,15), although these have not been specifically validated for the
intake of flavonoids. Moreover, flavanol and flavonol intake may
be underestimated, although our database was mostly complete
for these flavonoid subclasses (11,12), and herb/plant supplement
intakes were omitted in these analyses (up to 5% in Denmark, the
highest consuming country) (38). Nutritional biomarkers offer an
alternative method for estimating dietary intake that is objective
rather than subjective, and they provide more accurate measures
than self-reported questionnaires. To date, there are few validated
biomarkers of flavanol and flavonol intakes, so further research in
this field is warranted (39,40). The association of dietary flavanol
and flavonol intakes with T2D risk is likely susceptible to
confounding because high flavanol and flavonol intake reflects a
healthier lifestyle. In our models, we have adjusted for other
determinants of a healthy lifestyle; however, possible residual
confounding cannot be excluded. Finally, we realize that our study
is prone to the well-known drawback of multiple comparisons,
although Bender and Lange (41) concluded that adjustments for
multiple testing are not necessary in exploratory studies such as
this.
Strengths of the current study include the multicenter design
and the large sample size at recruitment, from whom a large
number of verified incident cases of T2D accrued during 3.99
million person-years of follow-up. This study also included a
wide variation in flavanol and flavonol intakes among partici-
pants in 8 European countries. Furthermore, we were able to
explore potential effect modifications and control for a number
of plausible confounders and factors that may hide the etiologic
pathway of the association between the intake of individual
TABLE 4 Pooled HRs (95% CIs) for the association between proanthocyanidin intakes and type 2 diabetes: the EPIC-InterAct study1
Proanthocyanidin Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P-trend2 Continuous (log2)
3
Dimers, mg/d ,14.1 14.1–22.1 22.2–32.3 33.4–49.5 .49.5
Median intake, mg/d 9.33 17.92 26.82 39.65 66.52
Model 1 1 (ref) 0.81 (0.73, 0.91) 0.75 (0.66, 0.85) 0.70 (0.59, 0.83) 0.66 (0.54, 0.81) ,0.001 0.86 (0.80, 0.92)
Model 2 1 (ref) 0.85 (0.73, 1.00) 0.89 (0.77, 1.03) 0.92 (0.82, 1.03) 0.85 (0.75, 0.96) 0.010 0.96 (0.93, 0.99)
Model 3 1 (ref) 0.85 (0.73, 0.99) 0.88 (0.75, 1.04) 0.89 (0.76, 1.03) 0.83 (0.73, 0.94) 0.003 0.94 (0.90, 0.99)
Model 4 1 (ref) 0.84 (0.72, 0.99) 0.87 (0.74, 1.02) 0.87 (0.74, 1.02) 0.81 (0.71, 0.92) 0.003 0.94 (0.90, 0.99)
Trimers, mg/d ,6.6 6.6–10.2 10.3–14.2 14.3–20.6 .20.6
Median intake, mg/d 4.4 8.36 12.12 16.79 27.03
Model 1 1 (ref) 0.87 (0.80, 0.94) 0.82 (0.73, 0.92) 0.78 (0.69, 0.88) 0.79 (0.69, 0.91) ,0.001 0.92 (0.88, 0.97)
Model 2 1 (ref) 0.94 (0.84, 1.06) 0.92 (0.79, 1.07) 0.96 (0.86, 1.07) 0.92 (0.82, 1.04) 0.045 0.97 (0.94, 1.00)
Model 3 1 (ref) 0.93 (0.84, 1.04) 0.90 (0.76, 1.07) 0.93 (0.80, 1.08) 0.92 (0.80, 1.06) 0.09 0.97 (0.93, 1.01)
Model 4 1 (ref) 0.93 (0.84, 1.03) 0.90 (0.77, 1.05) 0.93 (0.81, 1.07) 0.91 (0.80, 1.04) 0.07 0.97 (0.94, 1.01)
4–6mers, mg/d ,17.8 17.8–27.6 27.7–39.0 39.1–58.0 .58.0
Median intake, mg/d 11.92 22.67 32.9 46.57 78.33
Model 1 1 (ref) 0.87 (0.80, 0.94) 0.81 (0.74, 0.88) 0.81 (0.74, 0.89) 0.81 (0.73, 0.90) 0.001 0.92 (0.88, 0.97)
Model 2 1 (ref) 0.90 (0.82, 1.00) 0.89 (0.80, 1.00) 0.93 (0.83, 1.04) 0.88 (0.78, 1.00) 0.026 0.96 (0.93, 1.00)
Model 3 1 (ref) 0.91 (0.82, 1.01) 0.90 (0.80, 1.01) 0.95 (0.85, 1.07) 0.91 (0.80, 1.03) 0.12 0.97 (0.93, 1.00)
Model 4 1 (ref) 0.91 (0.82, 1.01) 0.89 (0.80, 1.00) 0.96 (0.85, 1.08) 0.92 (0.80, 1.05) 0.15 0.97 (0.95, 1.00)
7–10mers, mg/d ,2.3 12.3–19.6 19.6–28.7 28.8–42.8 .42.8
Median intake, mg/d 7.81 15.92 23.76 34.31 59.18
Model 1 1 (ref) 0.86 (0.78, 0.95) 0.83 (0.75, 0.92) 0.80 (0.72, 0.89) 0.83 (0.73, 0.93) 0.001 0.94 (0.91, 0.98)
Model 2 1 (ref) 0.92 (0.79, 1.07) 0.93 (0.82, 1.06) 0.91 (0.78, 1.05) 0.89 (0.78, 1.03) 0.030 0.98 (0.95, 1.00)
Model 3 1 (ref) 0.93 (0.80, 1.07) 0.94 (0.82, 1.08) 0.93 (0.80, 1.07) 0.92 (0.80, 1.07) 0.13 0.98 (0.96, 1.01)
Model 4 1 (ref) 0.92 (0.80, 1.06) 0.94 (0.82, 1.07) 0.94 (0.84, 1.06) 0.93 (0.81, 1.07) 0.15 0.98 (0.96, 1.01)
Polymers, mg/d .27.9 27.9–43.2 43.3–61.0 61.1–90.5 .90.5
Median intake, mg/d 18.78 35.57 51.35 72.95 118.27
Model 1 1 (ref) 0.86 (0.78, 0.95) 0.79 (0.72, 0.87) 0.81 (0.74, 0.89) 0.81 (0.71, 0.92) 0.003 0.94 (0.90, 0.98)
Model 2 1 (ref) 0.85 (0.75, 0.97) 0.86 (0.74, 1.01) 0.90 (0.81, 1.01) 0.88 (0.76, 1.00) 0.09 0.97 (0.94, 1.00)
Model 3 1 (ref) 0.85 (0.77, 0.94) 0.86 (0.74, 1.01) 0.92 (0.82, 1.03) 0.90 (0.80, 1.03) 0.31 0.98 (0.95, 1.01)
Model 4 1 (ref) 0.85 (0.77, 0.94) 0.85 (0.74, 0.98) 0.93 (0.82, 1.05) 0.92 (0.80, 1.06) 0.42 0.98 (0.96, 1.01)
1 For model 1, the pooled HRs were based on random-effects meta-analysis by using Prentice-weighted Cox regression analysis, stratified by center and adjusted for sex and total
energy intake. Model 2 was additionally adjusted for educational level, smoking status, physical activity levels, BMI, and alcohol intake. Model 3 was additionally adjusted for red
meat, processed meat, sugar-sweetened soft drink, and coffee intakes. Model 4 was additionally adjusted for fiber, vitamin C, and magnesium intakes. EPIC, European
Prospective Investigation into Cancer and Nutrition; ref, reference; 4–6mers, 4–6 monomers; 7–10mers, 7–10 monomers.
2 Obtained by assigning the median of each quintile as scores.
3 A 1-unit increase represents a doubling of proanthocyanidin intake.
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flavanols and flavonols and T2D. In all sensitivity analysis, the
associations were almost identical, denoting the robustness of
our results.
In conclusion, this large, prospective case-cohort study
supports a protective role for all individual flavan-3-ol mono-
mers, proanthocyanidins of low polymerization degree, and the
flavonol myricetin against T2D in men and women across
European countries. These results highlight the importance of
the assessment of individual flavonoids in addition to that of the
flavonoid subclasses. More studies in different populations are
needed to confirm these potential inverse associations between
the intake of individual flavanols and flavonols and the risk of
developing T2D.
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